Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
amplimed.com

See what CB Insights has to offer

Competitors

15

AmpliMed Competitors & Alternatives

15 Competitors

AmpliMed has 15 competitors. AmpliMed's competitors are Cellworks, Stemina Biomarker Discovery, Alfama, Santaris Pharma, NeurOP and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

6/30/2020

Series C

$37.88M

California

4/6/2020

Loan

$19.78M

Wisconsin

5/4/2017

Acquired

$4.18M

Portugal

8/4/2014

Acquired

$108.85M

Denmark

2/24/2014

Debt

$1.84M

Georgia

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

Latest Funding

6/30/2020

4/6/2020

5/4/2017

8/4/2014

2/24/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Investment Stage

Series C

Loan

Acquired

Acquired

Debt

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Total Funding

$37.88M

$19.78M

$4.18M

$108.85M

$1.84M

$99M

$99M

$99M

$99M

Mosaic

Location

California

Wisconsin

Portugal

Denmark

Georgia

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.